about
Crowdsourcing scoring of immunohistochemistry images: Evaluating Performance of the Crowd and an Automated Computational MethodAssessment of breast pathologies using nonlinear microscopyEMDomics: a robust and powerful method for the identification of genes differentially expressed between heterogeneous classes.Value of additional level sections in the evaluation of lymph nodes for endometrial carcinoma staging.A 63-Year-Old Man With Rapidly Progressive Dementia.Dual mTOR Kinase Inhibitor MLN0128 Sensitizes HR+/HER2+ Breast Cancer Patient-Derived Xenografts to Trastuzumab or Fulvestrant.Complete regression of cutaneous metastases with systemic immune response in a patient with triple negative breast cancer receiving p53MVA vaccine with pembrolizumab.Direct comparison between confocal and multiphoton microscopy for rapid histopathological evaluation of unfixed human breast tissue.Single molecule localization microscopy coupled with touch preparation for the quantification of trastuzumab-bound HER2An Automatable Method for Determining Adequacy of Thyroid Fine-Needle Aspiration SamplesClinical vs genomic risks in breast cancer in 2019: Breast pathologist's appellate review of the controversial results from TAILORx trialRaman Spectroscopy for Rapid Evaluation of Surgical Margins during Breast Cancer LumpectomyComprehensive Profiling of Poor-Risk Paired Primary and Recurrent Triple-Negative Breast Cancers Reveals Immune Phenotype ShiftsIdentification of Tissue-Specific DNA Methylation Signatures for Thyroid Nodule DiagnosticsMutation and immune profiling of metaplastic breast cancer: Correlation with survivalPhase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancerConnecting blood and intratumoral Treg cell activity in predicting future relapse in breast cancerPathway activity profiling of growth factor receptor network and stemness pathways differentiates metaplastic breast cancer histological subtypes
P50
Q30362485-05B25DA8-7AA5-46E4-A0C2-BF2FD3A21705Q34442060-A327D2AF-E6E9-4E65-BA7C-DAF5BE027919Q36551085-167DCDF9-E1A8-4AE5-904E-395F55982F07Q38138782-27394076-15B6-455C-B037-B15545CA1ADFQ42103943-E7D01409-1ECD-41FA-B358-AB65AF2A7F60Q46481299-45C57319-201F-4575-96EC-C15557916D5CQ47563512-F41CE3E5-DAA2-4544-BA73-A37988B24511Q51064844-04995D56-DB6B-4F9F-9B62-D4C6A1819BA2Q57477210-62A80DC8-61B6-4A5C-9BD3-E5C38769C054Q57789889-87C2C415-F0CA-437D-9EA9-52E35270D638Q89798104-52524A41-CFD7-492C-B182-8552CEF7828AQ90641398-B38F754E-C66E-40D8-AA4A-9A88EB9C0103Q90701319-860CC53C-A58B-454E-8259-C43B49A5F6FFQ90858660-91169FAD-0067-4921-B03D-3D9C284EB1ABQ91144844-1264DAF9-6726-400C-8BE0-49F735EED832Q91192834-8F5774E2-ADD4-4F5B-89E7-5F8E4C099271Q91724279-C949472A-FE0A-42ED-8AF8-58B6788932F2Q93128639-18421987-9D38-429B-9E97-BB614F39D84B
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Daniel Schmolze
@en
Daniel Schmolze
@nl
type
label
Daniel Schmolze
@en
Daniel Schmolze
@nl
prefLabel
Daniel Schmolze
@en
Daniel Schmolze
@nl
P31
P496
0000-0002-6947-2546